Edwards Lifesciences News
6 articles
growth-positive
Netflix upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
Jefferies upgraded AMD to Buy from Hold, raising the price target from $170 to $300. This upgrade is driven by OpenAIs plans to purchase six gigawatts of AMD equipment, which significantly changes AMDs AI narrative. The acquisition of such a large volume of equipment by OpenAI is expected to positively impact AMDs growth, reflecting the companys strong position in the AI technology market. The upgrade suggests confidence in AMDs potential for continued momentum and growth in the AI sector.
Customers
growth-positive
Edwards Lifesciences buys Israeli co Innovalve Bio Medical
Edwards Lifesciences has announced its intention to acquire Israeli medical device company Innovalve Bio Medical. The financial details of the acquisition have not been disclosed, but it is estimated to be worth hundreds of millions of dollars. Innovalve, which was founded at Sheba Medical Center, has previously signed a technology agreement with Edwards Lifesciences. The acquisition is expected to enhance Edwards trans-catheter mitral valve replacement technologies and support its long-term growth. Innovalve will join Edwards trans-catheter mitral and tricuspid therapies product group.
Acquisition
growth-positive
"Medicine is going to become much less invasive"
The article discusses Edwards Lifesciences, a US company that specializes in heart valves. The company acquired Israeli company PVT in 2004, which added a leading heart valve product to its offerings. Edwards still maintains a development center in Israel and has doubled its workforce since the acquisition. The company is focused on innovation and is looking for more acquisitions and collaborations in Israel. Edwards recently signed a deal with CollPlant, an Israeli company that develops products based on human collagen. The companies are working on a collagen-based component for heart valves, which could be worth tens of millions of dollars. Edwards has a market cap of $10 billion and annual sales of $1.4 billion. The CEO believes in the future of minimally invasive procedures and improving healthcare technology in developing countries.
AcquisitionPartners
growth-positive
Most Influential 2018: Edwards Lifesciences CEO Mike Mussallem leads company making medical breakthroughs
Edwards Lifesciences CEO Mike Mussallem has transformed the company from a debt-ridden spinoff into a leading manufacturer of replacement heart valves. Over the past 18 years, the companys value has increased by 4,000%, employment has doubled to nearly 13,000 in 40 nations, and its Irvine headquarters has expanded to 11 buildings on 40 acres. Mussallem has also been named to the Harvard Business Reviews list of the worlds best-performing CEOs four times in the past five years. In addition to its business success, Edwards Lifesciences is also committed to giving back to the community.
Management ChangesExpand
growth-positive
Edwards buys Israeli co Valtech Cardio for $1b
US company Edwards Lifesciences Corporation is acquiring Israeli valve repair device company Valtech Cardio Ltd. Edwards will pay Valtech $340 million in stock and cash at closing, with the potential for up to $350 million in milestone payments over the next 10 years and $300 million more for Valtechs early-stage transseptal mitral valve replacement technology program. The Cardioband System combines a reconstruction implant, similar to a surgical annuloplasty mitral valve repair device, with a transcatheter approach.
Acquisition
growth-positive
PVT medical technology firm sold to Edwards Lifesciences
Percutaneous Valve Technologies (PVT), an Israeli-American medical technology firm, is being acquired by Edwards Lifesciences Corporation for $155 million. The acquisition is expected to have a positive impact on PVTs growth. Aran R&D, a portfolio company of PVT, is selling its 5 percent stake in PVT for immediate revenues of $5.15 million. Other shareholders in PVT include Medica, Oxford BioScience Partners, Boston Scientific, Medtronic, and the founders and employees of the firm. PVT has tripled in value since its last funding round in January 2003. The acquisition is subject to due diligence and shareholder approval, with a target completion date in the first quarter of 2004.
Acquisition
